丁丙诺啡长效注射剂在阿片类物质使用障碍中的临床应用 - Suppr | 超能文献

Clinical applications of buprenorphine depot injection for opioid use disorder.

作者信息

Allikmets Silvia, Vink Jasper Pieter

机构信息

King's College London School of Medicine, London, UK.

Guy's and Saint Thomas' NHS Foundation Trust, London, UK.

出版信息

Addiction. 2020 Jan;115(1):190. doi: 10.1111/add.14818. Epub 2019 Nov 12.

DOI:10.1111/add.14818

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Clinical applications of buprenorphine depot injection for opioid use disorder.丁丙诺啡长效注射剂在阿片类物质使用障碍中的临床应用

Addiction. 2020 Jan;115(1):190. doi: 10.1111/add.14818. Epub 2019 Nov 12.

2

[Buprenorphine depot in opiate use disorder].[丁丙诺啡长效注射剂用于阿片类物质使用障碍]

Tijdschr Psychiatr. 2023;65(1):29-34.

3

Evaluation of an injection depot formulation of buprenorphine: placebo comparison.丁丙诺啡注射用长效制剂的评估：与安慰剂对比

Addiction. 2004 Nov;99(11):1439-49. doi: 10.1111/j.1360-0443.2004.00834.x.

4

Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.一种用于阿片类物质使用障碍患者每周一次给药的丁丙诺啡皮下长效注射剂（CAM2038）的药代动力学和药效学

J Subst Abuse Treat. 2017 Jul;78:22-29. doi: 10.1016/j.jsat.2017.04.008. Epub 2017 Apr 14.

5

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.阿片类药物使用障碍的丁丙诺啡注射剂：患者信息需求和偏好。

Drug Alcohol Rev. 2019 Jul;38(5):510-518. doi: 10.1111/dar.12939. Epub 2019 May 26.

6

Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.纳曲酮阻滞下健康志愿者中每周一次和每月一次丁丙诺啡皮下注射长效混悬剂（CAM2038）与静脉注射和舌下含服丁丙诺啡的药代动力学评估：一项开放标签的1期研究。

Adv Ther. 2017 Feb;34(2):560-575. doi: 10.1007/s12325-016-0472-9. Epub 2017 Jan 9.

7

An injection depot formulation of buprenorphine: extended bio-delivery and effects.丁丙诺啡注射长效制剂：延长生物给药及作用

Addiction. 2006 Mar;101(3):420-32. doi: 10.1111/j.1360-0443.2006.01348.x.

8

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.每月一次丁丙诺啡储库注射治疗阿片类药物使用障碍的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。

Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18.

9

A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.一项关于接受植入式纳曲酮、口服美沙酮或舌下含服丁丙诺啡治疗的阿片类物质使用障碍患者死亡率的回顾性队列研究。

Am J Drug Alcohol Abuse. 2019;45(3):285-291. doi: 10.1080/00952990.2018.1545131. Epub 2019 Mar 8.

10

[Buprenorphine vs. methadone as maintenance treatment for opioid dependence].[丁丙诺啡与美沙酮作为阿片类药物依赖维持治疗的比较]

Nervenarzt. 1999 Sep;70(9):795-802. doi: 10.1007/s001150050514.

引用本文的文献

1

Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations.阿片类物质使用障碍治疗的最新进展——聚焦于长效丁丙诺啡制剂

World J Psychiatry. 2021 Sep 19;11(9):543-552. doi: 10.5498/wjp.v11.i9.543.